No gioke intended

Research output: Contribution to journalArticlepeer-review

Abstract

The optimal prophylactic agent for PCP that is currently available is TMP-SMZ; however, this combination is not tolerated by 34% of HIV-infected patients [2]. AP (300 mg/mo) is a secondline agent as, in comparison with TMP-SMZ, it is less efficacious for prophylaxis of PCP, more costly, and not prophylactic for extrapulmonary pneumocystosis [3, 4]. Our patient developed PCP while he was taking AP (300 mg/mo), and he exhibited intolerance to other accepted prophylactic agents. We empiricallyrestarted treatment with AP at a dose of 600 mg twice per month (quadrupling the usual monthly dose), and this regimen was successful as secondary prophylaxis for our patient for> i year.

Original languageEnglish (US)
Pages (from-to)258
Number of pages1
JournalClinical Infectious Diseases
Volume18
Issue number2
DOIs
StatePublished - Feb 1994

Fingerprint Dive into the research topics of 'No gioke intended'. Together they form a unique fingerprint.

Cite this